# ClinicalTrials.gov record NCT04943159

> PeptideScanner retained ClinicalTrials.gov record NCT04943159 at 2026-07-30T19:57:27.404Z. Its registry update date was 2021-10-26, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct04943159-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04943159-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04943159-afamelanotide-v1.json
- Content SHA-256: `7e2ee44a726f4f7fc4528de4d5a289a1ed0f7a9e98983b8708c9703629244ddb`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04943159 ([`ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c`](#source-ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04943159 at 2026-07-30T19:57:27.404Z. Its registry update date was 2021-10-26, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c`](#source-ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04943159 at 2026-07-30T19:57:27.404Z. Its registry update date was 2021-10-26, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c`](#source-ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c`](#source-ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c))

## Sources

<a id="source-ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c"></a>
- **ClinicalTrials.gov record NCT04943159 · retained source version 2021-10-26:bdb90ad62b1cb218e1fd0336e359abc708bc5e6652d4c0909485ad80856db7ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04943159) (`ctg-observation-nct04943159-2021-10-26-bdb90ad62b1c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04943159." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04943159-afamelanotide-v1.json SHA-256: 7e2ee44a726f4f7fc4528de4d5a289a1ed0f7a9e98983b8708c9703629244ddb.